You are here

  • Home
  • Archive
  • Volume 7, Issue 6
  • Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study

Article Text

Article menu

Download PDFPDF

XML
Cardiovascular medicine
Research
Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study
  1. Sheng-Hua Yang,
  2. Ying Du,
  3. Yan Zhang,
  4. Xiao-Lin Li,
  5. Sha Li,
  6. Rui-Xia Xu,
  7. Cheng-Gang Zhu,
  8. Yuan-Lin Guo,
  9. Na-Qiong Wu,
  10. Ping Qing,
  11. Ying Gao,
  12. Chuan-Jue Cui,
  13. Qian Dong,
  14. Jing Sun,
  15. Jian-Jun Li, Corresponding author
  1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
  1. Correspondence to Professor Jian-Jun Li; lijianjun938{at}126.com

Abstract

Objectives The aim of this study was to investigate the association of serum fibrinogen with cardiovascular events (CVE) in Chinese patients with type 2 diabetes mellitus (T2DM) and stable coronary artery disease (CAD).

Design An observational study.

Setting FuWai Hospital in Beijing, China.

Participants A cohort of 1466 patients with T2DM and angiographic-proven stable CAD was evaluated.

Outcome measures Baseline serum fibrinogen levels were measured and trisected into ‘low’, ‘middle’ and ‘high’. Their association with CVE was explored using Cox proportional hazard models.

Results With 20.2 months (average) follow-up, 44 (3%) were lost to follow-up and 96 patients developed CVE. Compared with the patients without CVE, the ones who developed CVE had higher levels of fibrinogen. Univariable regression revealed a significant relation of fibrinogen to CVE (HR (HR) 1.25, 95% CI 1.06 to 1.47, p=0.010) per SD increase of fibrinogen at baseline. After adjusting for multiple established cardiovascular disease (CVD) risk factors, the association persisted (HR 1.30, 95% CI 1.02 to 1.66, p=0.037). Moreover, after adjusting for CVD risk factors, the HRs for middle-serum and high-serum fibrinogen concentration, using ‘low’ group as reference, were 1.23 (95% CI 0.69 to 2.20) and 2.20 (95% CI 1.11 to 3.36, p=0.049).

Conclusions We first indicated that elevated fibrinogen level was independently associated with increased CVE in Chinese patients with T2DMand stable CAD.

  • Fibrinogen
  • type 2 diabetes mellitus
  • coronary artery disease
  • outcome

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjopen-2016-015041

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors S-HY analysed the data and drafted the manuscript. J-JL planned and designed the study. The rest of the authors were involved in collecting and researching data, reviewing and editing manuscript. All authors read and approved the final manuscript.

    • Funding This work was partially supported by Youth Foundation of Peking Union Medical College (3332016023), the National Natural Science Foundation of China (81070171, 81241121), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20111106110013), the Capital Special Foundation of Clinical Application Research (Z121107001012015), the Capital Health Development Fund (2011400302) and the Beijing Natural Science Foundation (7131014) awarded to Dr Jian-Jun Li, MD, PhD.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval The study was performed according to the Declaration of Helsinki, and the hospital ethics review board (Fuwai Hospital and National Center for Cardiovascular Diseases, Beijing, China) approved the protocol.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement The technical appendix, statistical code and data set are available from the corresponding author.